Department of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universi-tät Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany
Francesco Ansideri
Department of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universi-tät Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany
Stanislav Andreev
Department of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universi-tät Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany
Dieter Schollmeyer
Department of Organic Chemistry, Johannes Gutenberg-University Mainz, Duesbergweg 10-14, 55099 Mainz, Germany
Stefan Laufer
Department of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universi-tät Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany
Pierre Koch
Department of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universi-tät Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany
The title compound N1-{4-[2-(methylthio)-1H-imidazol-5-yl]pyridin-2-yl}benzene-1,4-diamine (2) was synthesized via nucleophilic aromatic substitution of 2-chloro-4-[2-(methylthio)-1H-imidazol-5-yl]pyridine (3) and p-phenylenediamine under acidic conditions. The synthesized compound 2 was characterized by 1H-NMR, 13C-NMR, MS HPLC, IR and UV-VIS. Additionally, the structure of 2 was confirmed by single crystal X-ray diffraction. Pyridinylimidazole 2 displays moderate affinity towards the c-Jun N-terminal kinase 3 and shows selectivity versus the closely related p38α mitogen-activated protein kinase.
